LIBTAYO as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Jun 19, 2025 · LIBTAYO 350 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by Regeneron UK Limited

LIBTAYO is a clear to slightly opalescent, colorless to pale yellow solution that may contain trace amounts of translucent to white particles. Discard the vial if the solution is cloudy, discolored or …

LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6. The solution may contain trace amounts of …

Cervical Cancer LIBTAYO (cemiplimab for injection) is indicated for: • the treatment of adult patients with cervical cancer who have progressed on or after prior platinum-based …

LIBTAYO is for intravenous use. It is administered by intravenous infusion over 30 minutes through an intravenous line containing a sterile, non-pyrogenic, low-protein binding, in-line or …

LIBTAYO is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 …

LIBTAYO Concentrate for solution for infusion Ref. [8754] Active ingredients: Cemiplimab Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Regeneron Ireland …

Jul 5, 2019 · Libtayo is a cancer medicine used in adults to treat: a type of skin cancer called cutaneous squamous cell carcinoma when the cancer is locally advanced (has spread nearby) …

Permanently discontinue LIBTAYO for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic …